HE is a potentially fatal brain disorder that is caused by liver damage, which results in the failure to remove toxins from the blood.
The availability of patient-focused programs to assist disease management is one of the primary growth drivers for the global hepatic encephalopathy (HE) therapeutics market till 2023. Such programs increase the adherence to therapeutics by improving convenience for patients. Norgine collaborated with the European liver patients association (ELPA) to launch Time to DeLiver program, which is focused on changing the perception about HE among all stakeholders, healthcare professionals, and policymakers. This in turn, drives the demand for diagnosis and management of HE.
The most commonly used therapeutics to treat HE are lactulose and rifaximin. Researchers are also developing treatments that targets ammonia production and removal. For instance, AST-120 is under investigation and targets gut-derived toxins for liver cirrhosis. It can also be used to treat HE. The progression and development of HE sometimes depends on factors such as inflammation. This is compelling researchers to introduce various treatments that targets inflammation. Some of the most recent approaches to treat HE includes probiotics, albumin administration, and dialysis. Such emergence of novel hepatic encephalopathy treatment targets is identified as one of the key trends that will stimulate growth in the hepatic encephalopathy (HE) therapeutics market during the forecasted period.
The global Hepatic Encephalopathy (HE) Therapeutics market is valued at xx million US$ in 2018 is expected to reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025.
This report focuses on Hepatic Encephalopathy (HE) Therapeutics volume and value at global level, regional level and company level. From a global perspective, this report represents overall Hepatic Encephalopathy (HE) Therapeutics market size by analyzing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and Japan.
At company level, this report focuses on the production capacity, ex-factory price, revenue and market share for each manufacturer covered in this report.
The following manufacturers are covered:
ASKA Pharmaceutical
COSMO PHARMACEUTICALS
Mallinckrodt
Valeant
...
Segment by Regions
North America
Europe
China
Japan
Segment by Type
Lactulose
Rifaximin
Neomycin
Probiotics
Thiamine
Segment by Application
Acute Liver Failure
Portal Systemic Bypass Without Liver Disease
Liver Cirrhosis
Summary: Get latest Market Research Reports on Hepatic Encephalopathy (HE) Therapeutics. Industry analysis & Market Report on Hepatic Encephalopathy (HE) Therapeutics is a syndicated market report, published as Global Hepatic Encephalopathy (HE) Therapeutics Market Research Report 2019. It is complete Research Study and Industry Analysis of Hepatic Encephalopathy (HE) Therapeutics market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.